


CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein;

~~W is NHa heteroatom selected from N or O, wherein N is substituted with hydrogen, C₁-C₆ alkyl or C₃-C₅ cycloalkyl;~~


~~Y is Oselected in the group consisting of: a group S(O)_p wherein p is 0, 1 or 2; a group O(CR³R⁴)_n; a group; (CR⁵R⁶)_n; a group NR⁷; a group OC(O); a group OC(O)NH; and a group OC(O)O;~~

~~R³, R⁴, R⁵ and R⁶ are each independently hydrogen, fluorine or C₁-C₆ alkyl, or, respectively, R³ and R⁴, or R⁵ and R⁶ may form together with the carbon atom to which they are attached a saturated 3-6 membered carbocyclic monocyclic ring optionally substituted by a group C₁-C₆ alkyl, hydroxyl or halo;~~


~~n is 0, 1, 2 or 3;~~

~~R⁷ is hydrogen, C₁-C₆ alkyl, or C₃-C₇ cycloalkyl wherein such C₁-C₆ alkyl or C₃-C₇ cycloalkyl are optionally substituted by a group C₁-C₃ alkyl, C₃-C₆ cycloalkyl, hydroxyl, cyano or halo;~~


R¹ is a group selected from (IIa) - (IIc):



(IIa)



(IIb)



(IIc)

R⁸ and R⁹ are each independently hydrogen or C₁-C₆ alkyl, or R⁸ and R⁹ may form together with the nitrogen atom to which they are attached a 5-11- membered saturated monocyclic or a fused or spiro bicyclic ring system optionally containing a further heteroatom which is oxygen or nitrogen, said nitrogen atom being optionally substituted by C₁-C₆ alkyl; wherein such C₁-C₆

alkyl groups may be optionally substituted by a group C₁-C₆ alkyl, C₃-C₆ cycloalkyl, hydroxyl or halo;

X¹, X², X³, X⁴ and X⁵ are each independently a carbon atom, a nitrogen atom, a group -(CH)- or a group -NH-; such that each combination thereof forms an aromatic ring system;

R¹⁰ is selected from a group consisting of: Hydrogen, -NR^AR^B, -N(R^C)(C₂-C₆alkylene)-NR^AR^B, -N(R^C)(C₃-C₇cycloalkylene)-NR^AR^B, -(C₁-C₆alkylene)-NR^AR^B, -(C₃-C₇cycloalkylene)-NR^AR^B, -O-(C₂-C₆alkylene)-NR^AR^B, -O-(C₃-C₇cycloalkylene)-NR^AR^B, -S-(C₂-C₆alkylene)-NR^AR^B, -S-(C₃-C₇cycloalkylene)-NR^AR^B, -N(R^C)C(O)-(C₁-C₆alkylene)-NR^AR^B, -N(R^C)C(O)-(C₃-C₇cycloalkylene)-NR^AR^B, -C(O)N(R^C)-(C₂-C₆alkylene)-NR^AR^B, -C(O)N(R^C)-(C₃-C₇cycloalkylene)-NR^AR^B, -C(O)N(R^C)-(C₂-C₆alkylene)-OR^D, -C(O)N(R^C)-(C₃-C₇cycloalkylene)-OR^D, -N(R^C)C(O)NR^AR^B, -C(O)NR^AR^B, -N(R^C)C(O)N(R^C)-(C₂-C₆alkylene)-NR^AR^B, -N(R^C)C(O)N(R^C)-(C₃-C₇cycloalkylene)-NR^AR^B, -(C₂-C₆alkylene)-OR^D, -(C₃-C₇cycloalkylene)-OR^D, -O-(C₂-C₆alkylene)-OR^D, -O-(C₃-C₇cycloalkylene)-OR^D, -S-(C₂-C₆alkylene)-OR^D, -S-(C₃-C₇cycloalkylene)-OR^D, -N(R^C)S(O)₂-(C₁-C₆alkylene)-NR^AR^B, -N(R^C)S(O)₂-(C₃-C₇cycloalkylene)-NR^AR^B, -S(O)₂N(R^C)-(C₂-C₆alkylene)-NR^AR^B, -S(O)₂N(R^C)-(C₃-C₇cycloalkylene)-NR^AR^B, -S(O)₂N(R^C)-(C₂-C₆alkylene)-OR^D, -S(O)₂N(R^C)-(C₃-C₇cycloalkylene)-OR^D, -N(R^C)S(O)₂-(C₂-C₆alkylene)-OR^D, -N(R^C)S(O)₂-(C₃-C₇cycloalkylene)-OR^D, -S(O)₂N(R^AR^B), -N(R^C)S(O)₂R^D, -N(R^C)C(O)R^C, -OR^C, -SR^C, -(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl), (C₅-C₇heterocycloalkyl)(C₃-C₆cycloalkyl)-, and C₃-C₇ heterocycloalkylcarbonyl; wherein any of such C₁-C₆alkyl, C₃-C₆cycloalkyl, -(C₁-C₆alkylene)-, -(C₂-C₆alkylene)-, -(C₃-C₇cycloalkylene)-, -(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl), (C₅-C₇heterocycloalkyl)-(C₃-C₆cycloalkyl) and (C₃-C₇heterocycloalkyl)carbonyl portion in the above listed groups may be optionally substituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl, hydroxyl or halo;

R¹¹ is linked to X⁴ and is selected from a group consisting of:

Hydrogen; -CN; C₁-C₆ alkyl which is substituted by a group selected from -CN, -OR^C, -SR^C, halo; C₃-C₆cycloalkyl which is substituted by a group selected

- from C₁-C₄ alkyl, -CN, -OR^C, -SR^D, halo; -NR^AR^B, -N(R^C)(C₂-C₆alkylene)-NR^AR^B, -N(R^C)(C₃-C₇cycloalkylene)-NR^AR^B, -(C₁-C₆alkylene)-NR^AR^B, -(C₃-C₇cycloalkylene)-NR^AR^B, -O-(C₂-C₆alkylene)-NR^AR^B, -O-(C₃-C₇cycloalkylene)-NR^AR^B, -S-(C₂-C₆alkylene)-NR^AR^B, -S-(C₃-C₇cycloalkylene)-NR^AR^B, -
- 5 N(R^C)C(O)-(C₁-C₆alkylene)-NR^AR^B, -N(R^C)C(O)-(C₃-C₇cycloalkylene)-NR^AR^B, -C(O)N(R^C)-(C₂-C₆alkylene)-NR^AR^B, -C(O)N(R^C)-(C₃-C₇cycloalkylene)-NR^AR^B, -C(O)N(R^C)-(C₂-C₆alkylene)-OR^D, -C(O)N(R^C)-(C₃-C₇cycloalkylene)-OR^D, -N(R^C)C(O)N(R^AR^B), -C(O)N(R^AR^B), -N(R^C)C(O)N(R^C)-(C₂-C₆alkylene)-NR^AR^B, -N(R^C)C(O)N(R^C)-(C₃-C₇cycloalkylene)-NR^AR^B, -O-(C₂-C₆alkylene)-OR^D, -O-(C₃-
- 10 C₇cycloalkylene)-OR^D, -S-(C₂-C₆alkylene)-OR^D, -S-(C₃-C₇cycloalkylene)-OR^D, -N(R^C)S(O)₂-(C₁-C₆alkylene)-NR^AR^B, -N(R^C)S(O)₂-(C₃-C₇cycloalkylene)-NR^AR^B, -S(O)₂N(R^C)-(C₂-C₆alkylene)-NR^AR^B, -S(O)₂N(R^C)-(C₃-C₇cycloalkylene)-NR^AR^B, -S(O)₂N(R^C)-(C₂-C₆alkylene)-OR^D, -S(O)₂N(R^C)-(C₃-C₇cycloalkylene)-OR^D, -N(R^C)S(O)₂-(C₂-C₆alkylene)-OR^D, -N(R^C)S(O)₂-(C₃-C₇cycloalkylene)-OR^D, -
- 15 S(O)₂N(R^AR^B), -N(R^C)S(O)₂R^D, -N(R^C)C(O)R^C, OR^C, SR^C, -(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl), (C₅-C₇heterocycloalkyl)(C₃-C₆cycloalkyl) and (C₃-C₇ heterocycloalkyl)carbonyl, wherein any of such C₁-C₆alkyl, C₃-C₆cycloalkyl, -(C₁-C₆alkylene)-, -(C₂-C₆alkylene)-, -(C₃-C₇cycloalkylene)-, -(C₃-C₇heterocycloalkyl), (C₅-
- 20 C₇heterocycloalkyl)-(C₁-C₆ alkyl), (C₅-C₇ heterocycloalkyl)-(C₃-C₆ cycloalkyl) and (C₃-C₇heterocycloalkyl)carbonyl portion in the above listed groups may be optionally substituted by one, two or three groups **R**²⁵ which are independently selected in the list consisting of: C₁-C₆ alkyl, (C₁-C₃) haloalkyl, (C₁-C₄)hydroxyalkyl, C₃-C₇ cycloalkyl, hydroxyl and halo; or
- 25 **R**¹¹ is linked to X⁴ and is phenyl or 5- or 6-membered monocyclic heteroaryl, wherein such phenyl or 5- or 6-membered monocyclic heteroaryl is substituted by a group selected in the list consisting of: C₁-C₆ alkyl which is substituted by a group -CN; C₃-C₆ cycloalkyl which is substituted by a group selected from: -CN, -OR^C, -SR^C or halo; -N(R^C)(C₂-C₆alkylene)-NR^AR^B, -N(R^C)(C₃-C₇cycloalkylene)-NR^AR^B, -(C₁-C₆alkylene)-NR^AR^B, -(C₃-C₇cycloalkylene)-NR^AR^B, -O-(C₃-C₇cycloalkylene)-NR^AR^B, -S-(C₂-C₆alkylene)-NR^AR^B, -S-(C₃-C₇cycloalkylene)-NR^AR^B, -N(R^C)C(O)-(C₁-C₆alkylene)-NR^AR^B, -
- 30

- $N(R^C)C(O)-(C_3-C_7\text{cycloalkylene})-NR^A R^B$, $-C(O)N(R^C)-(C_2-C_6\text{alkylene})-NR^A R^B$, $-C(O)N(R^C)-(C_3-C_7\text{cycloalkylene})-NR^A R^B$, $-C(O)N(R^C)-(C_2-C_6\text{alkylene})-OR^D$, $-C(O)N(R^C)-(C_3-C_7\text{cycloalkylene})-OR^D$, $-N(R^C)C(O)N(R^C)-(C_2-C_6\text{alkylene})-NR^A R^B$, $-N(R^C)C(O)N(R^C)-(C_3-C_7\text{cycloalkylene})-NR^A R^B$, $-O-(C_3-C_7\text{cycloalkylene})-OR^D$, $-S-(C_3-C_7\text{cycloalkylene})-OR^D$, $-N(R^C)S(O)_2-(C_1-C_6\text{alkylene})-NR^A R^B$, $-N(R^C)S(O)_2-(C_3-C_7\text{cycloalkylene})-NR^A R^B$, $-S(O)_2N(R^C)-(C_2-C_6\text{alkylene})-NR^A R^B$, $-S(O)_2N(R^C)-(C_3-C_7\text{cycloalkylene})-NR^A R^B$, $-S(O)_2N(R^C)-(C_2-C_6\text{alkylene})-OR^D$, $-S(O)_2N(R^C)-(C_3-C_7\text{cycloalkylene})-OR^D$, $-N(R^C)S(O)_2-(C_2-C_6\text{alkylene})-OR^D$, $-N(R^C)S(O)_2-(C_3-C_7\text{cycloalkylene})-OR^D$, $-N(R^C)S(O)_2R^D$, $-(C_3-C_7\text{heterocycloalkyl})$, $(C_5-C_7\text{heterocycloalkyl})-(C_1-C_6\text{alkyl})$, $(C_5-C_7\text{heterocycloalkyl})(C_3-C_6\text{cycloalkyl})$ and $(C_3-C_7\text{heterocycloalkyl})\text{carbonyl}$, wherein any of such $C_1-C_6\text{alkyl}$, $C_3-C_6\text{cycloalkyl}$, $-(C_1-C_6\text{alkylene})-$, $-(C_2-C_6\text{alkylene})-$, $-(C_3-C_7\text{cycloalkylene})-$, $-(C_3-C_7\text{heterocycloalkyl})$, $(C_5-C_7\text{heterocycloalkyl})-(C_1-C_6\text{alkyl})$, $(C_5-C_7\text{heterocycloalkyl})-(C_3-C_6\text{cycloalkyl})$ and $(C_3-C_7\text{heterocycloalkyl})\text{carbonyl}$ portion in the above listed groups may be optionally substituted by one, two or three groups R^{25} which are independently selected in the group consisting of: $C_1-C_6\text{alkyl}$, $(C_1-C_3)\text{ haloalkyl}$, $(C_1-C_4)\text{hydroxyalkyl}$, $C_3-C_7\text{cycloalkyl}$, hydroxyl and halo;

- R^A and R^B are at each occurrence independently hydrogen, $C_1-C_6\text{ alkyl}$ or $C_3-C_7\text{ cycloalkyl}$, such $C_1-C_6\text{ alkyl}$ and $C_3-C_7\text{ cycloalkyl}$ being optionally substituted by a group $C_1-C_3\text{ alkyl}$, $C_3-C_7\text{cycloalkyl}$, $-OR^D$, $-CN$ or halo; alternatively, R^A and R^B , may form together with the nitrogen atom to which they are attached a 5-11- membered saturated heterocyclic monocyclic or bicyclic ring system which is optionally substituted by one or more group $-OR^D$, $-CN$, halo, $C_1-C_6\text{ alkyl}$ or $C_3-C_7\text{ cycloalkyl}$, such $C_1-C_6\text{ alkyl}$ and $C_3-C_7\text{ cycloalkyl}$ being optionally substituted by a group $C_1-C_3\text{ alkyl}$, $C_3-C_7\text{cycloalkyl}$, $-OR^D$, $-CN$ or halo; and which 5-11- membered saturated heterocyclic monocyclic or bicyclic ring optionally contains a further heteroatom which is oxygen or nitrogen, said nitrogen atom optionally substituted by $C_1-C_6\text{ alkyl}$ or $C_3-C_6\text{ cycloalkyl}$, wherein any of such $C_1-C_6\text{ alkyl}$ or $C_3-C_6\text{ cycloalkyl}$ may be optionally substituted by a group $C_1-C_6\text{ alkyl}$, $C_3-C_7\text{ cycloalkyl}$, $-OR^D$, $-CN$, or halo; and/or R^A and R^B may be linked to one carbon atom of the $-(C_1-C_6\text{alkylene})-$, $-(C_2-C_6\text{alkylene})-$ or $-(C_3-$

C₇cycloalkylene)- portion of the group linked to the nitrogen to which they are connected to form a saturated cycle of up to 6 ring atoms;

R^C is at each occurrence independently hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl, such C₁-C₆ alkyl and C₃-C₆ cycloalkyl being optionally substituted by a group C₁-C₃ alkyl, -OR^D, -CN or halo;


R^D is at each occurrence independently hydrogen, -CH₃ or -C₂H₅;

R¹² and **R¹³** are independently hydrogen, C₁-C₆ alkyl, or halogen;


A is a divalent cycloalkylene radical having 5, 6 or 7 ring atoms; said cycloalkylene ring being attached to W and Y, and fused to a phenyl ring or to a monocyclic heteroaryl ring having 5 or 6 ring atoms, such phenyl or heteroaryl ring being optionally substituted by one or two groups R²⁴;

R²⁴ is at each occurrence independently selected from the group consisting of: C₁-C₆ alkyl, halogen and cyano;


R² is a radical of formula (IIIa), (IIIb), (IIIc), or (IIId):




(IIIa)



(IIIb)



(IIIc)



(IIId)


wherein

R¹⁴ is selected in the group consisting of: -F, -CH₃, -C₂H₅, -CH₂OH, -CH₂OMe, -CF₂CF₃, -CH₂SCH₃, -SCH₃ and -SC₂H₅;

R¹⁵ and **R¹⁶** are independently -CH₃ or -C₂H₅;

R¹⁷ is selected from the group consisting of: lone electron pair, hydrogen, -CF₃, -NR^ER^F, -(C₃-C₇cycloalkyl), -(C₃-C₇heterocycloalkyl), aryl or heteroaryl wherein any of such -(C₃-C₇cycloalkyl), -(C₃-C₇heterocycloalkyl), aryl or heteroaryl may be optionally substituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl, or halo; or

R¹⁷ is a group of general formula (IV)



wherein

R^{20} is selected in the group consisting of: -F, -CH₃, -C₂H₅, -CH₂OH, -CH₂OMe, -CF₂CF₃, -CH₂SCH₃, -SCH₃ and -SC₂H₅;

5 R^{21} is -CH₃ or -C₂H₅;

or

R^{20} and R^{21} as defined above may form together with the carbon atom to which they are attached a saturated 3-7- membered monocyclic ring;

R^E and R^F are each independently C₁-C₆ alkyl, optionally substituted by a group C₁-C₃ alkyl, -OR^G, -CN or halo; alternatively, R^E and R^F may form together with the nitrogen atom to which they are attached a 5-11- membered saturated monocyclic or bicyclic heterocyclic ring system which is optionally substituted by one or more groups -OR^G, -CN, halo, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, such C₁-C₆ alkyl and C₃-C₇ cycloalkyl being optionally substituted by a group C₁-C₃ alkyl, C₃-C₇ cycloalkyl, -OR^G, -CN or halo; and which 5-11- membered saturated monocyclic or bicyclic heterocyclic ring optionally contains a further heteroatom which is oxygen or nitrogen, said nitrogen atom optionally substituted by C₁-C₆ alkyl or C₃-C₆ cycloalkyl, wherein any of such C₁-C₆ alkyl or C₃-C₆ cycloalkyl may be optionally substituted by a group C₁-C₆ alkyl or C₃-C₇ cycloalkyl;

20 R^G is hydrogen, -CH₃ or -C₂H₅;

R^{18} is selected in the group consisting of: lone electron pair, hydrogen, aryl, heteroaryl, -(C₁-C₆alkyl), -(C₃-C₇cycloalkyl), -(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) and (C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl), wherein any of such aryl, heteroaryl, -(C₁-C₆alkyl), -(C₃-C₇cycloalkyl), -(C₃-C₇heterocycloalkyl), (C₅-C₇heterocycloalkyl)-(C₁-C₆alkyl) and (C₅-C₇heterocycloalkyl)-(C₃-C₆ cycloalkyl) may be optionally substituted by a group -CN, -OH, halo, -COOR^M, C₁-C₆alkyl, C₃-C₆cycloalkyl, -O-(C₁-C₆alkyl), -O-(C₃-C₆cycloalkyl), -S-(C₁-C₆alkyl), -S-(C₃-C₆cycloalkyl), -NR^HR^J, -N(R^L)(C₂-C₆alkylene)-NR^HR^J, -N(R^L)(C₃-C₇cycloalkylene)-NR^HR^J, -(C₁-C₆alkylene)-NR^HR^J,

- $-(C_3-C_7\text{cycloalkylene})-NR^HR^J$, $-O-(C_2-C_6\text{alkylene})-NR^HR^J$, $-O-(C_3-C_7\text{cycloalkylene})-NR^HR^J$, $-S-(C_2-C_6\text{alkylene})-NR^HR^J$, $-S-(C_3-C_7\text{cycloalkylene})-NR^HR^J$, $-N(R^L)C(O)-(C_1-C_6\text{alkylene})-NR^HR^J$, $-N(R^L)C(O)-(C_3-C_7\text{cycloalkylene})-NR^HR^J$, $-C(O)N(R^L)-(C_2-C_6\text{alkylene})-NR^HR^J$,
 5 $-C(O)N(R^L)-(C_3-C_7\text{cycloalkylene})-NR^HR^J$, $-C(O)N(R^L)-(C_2-C_6\text{alkylene})-OR^M$, $-C(O)N(R^L)-(C_3-C_7\text{cycloalkylene})-OR^M$, $-N(R^L)C(O)N(R^HR^J)$, $-C(O)N(R^HR^J)$, $-N(R^L)C(O)N(R^L)-(C_2-C_6\text{alkylene})-NR^HR^J$, $-N(R^L)C(O)N(R^L)-(C_3-C_7\text{cycloalkylene})-NR^HR^J$, $-O-(C_2-C_6\text{alkylene})-OR^M$, $-O-(C_3-C_7\text{cycloalkylene})-OR^M$, $-S-(C_2-C_6\text{alkylene})-OR^M$, $-S-(C_3-C_7\text{cycloalkylene})-OR^M$, $-N(R^L)S(O)_2-(C_1-C_6\text{alkylene})-NR^HR^J$,
 10 $-N(R^L)S(O)_2-(C_3-C_7\text{cycloalkylene})-NR^HR^J$, $-S(O)_2N(R^L)-(C_2-C_6\text{alkylene})-NR^HR^J$, $-S(O)_2N(R^L)-(C_3-C_7\text{cycloalkylene})-NR^HR^J$, $-S(O)_2N(R^L)-(C_2-C_6\text{alkylene})-OR^M$, $-S(O)_2N(R^L)-(C_3-C_7\text{cycloalkylene})-OR^M$, $-N(R^L)S(O)_2-(C_2-C_6\text{alkylene})-OR^M$, $-N(R^L)S(O)_2-(C_3-C_7\text{cycloalkylene})-OR^M$, $-S(O)_2N(R^HR^J)$, $-N(R^L)S(O)_2R^L$, $-N(R^L)C(O)R^L$, OR^L , SR^L , $-(C_3-C_7\text{heterocycloalkyl})$, $(C_5-C_7\text{heterocycloalkyl})-(C_1-C_6\text{ alkyl})$ and $(C_5-C_7\text{heterocycloalkyl})-(C_3-C_6\text{ cycloalkyl})$, wherein any of such $C_1-C_6\text{ alkyl}$, $C_3-C_6\text{ cycloalkyl}$, $-(C_1-C_6\text{alkylene})-$, $-(C_2-C_6\text{alkylene})-$, $-(C_3-C_7\text{cycloalkylene})-$, $-(C_3-C_7\text{heterocycloalkyl})$, $(C_5-C_7\text{heterocycloalkyl})-(C_1-C_6\text{ alkyl})$ and $(C_5-C_7\text{heterocycloalkyl})-(C_3-C_6\text{ cycloalkyl})$ portion in the above listed groups may be
 15 optionally substituted by a group $C_1-C_6\text{ alkyl}$, $C_3-C_7\text{ cycloalkyl}$, $-OR^L$ or halo;

R^H and R^J , are at each occurrence independently hydrogen, $C_1-C_6\text{ alkyl}$ or $C_3-C_6\text{ cycloalkyl}$, such $C_1-C_6\text{ alkyl}$ or $C_3-C_6\text{ cycloalkyl}$ being optionally substituted by a group $C_1-C_3\text{ alkyl}$, $-OR^M$, CN or halo;

- alternatively, R^H and R^J may also together with the nitrogen atom to which
 25 they are attached a 5-11- membered saturated monocyclic or bicyclic heterocyclic ring system which is optionally substituted by one or more groups $-OR^M$, $-CN$, halo, $C_1-C_6\text{ alkyl}$ or $C_3-C_7\text{ cycloalkyl}$, such $C_1-C_6\text{ alkyl}$ and $C_3-C_7\text{ cycloalkyl}$ being optionally substituted by a group $C_1-C_3\text{ alkyl}$, $C_3-C_7\text{cycloalkyl}$, $-OR^M$, CN or halo; and which 5-11- membered saturated monocyclic or bicyclic heterocyclic ring
 30 optionally contains a further heteroatom which is oxygen or nitrogen, said nitrogen atom optionally substituted by $C_1-C_6\text{ alkyl}$ or $C_3-C_6\text{ cycloalkyl}$, wherein any of such $C_1-C_6\text{ alkyl}$ or $C_3-C_6\text{ cycloalkyl}$ may be optionally substituted by a group C_1-

C₆ alkyl, C₃-C₇ cycloalkyl, -OR^M, CN, or halo;

and/or R^H and R^J may be linked to one carbon atom of the -(C₁-C₆alkylene)-, -(C₂-C₆alkylene)- or -(C₃-C₇cycloalkylene)- portion of the group linked to the nitrogen to which they are connected to form a saturated cycle of up to 6 ring atoms;


R^L is at each occurrence independently hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl, such C₁-C₆ alkyl or C₃-C₆ cycloalkyl being optionally substituted by a group C₁-C₃ alkyl, -OR^M, -CN or halo;

R^M is at each occurrence independently hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl, such C₁-C₆ alkyl or C₃-C₆ cycloalkyl being optionally substituted by a group hydroxyl, -CN or halo;

z¹, z², z³, and z⁴ are independently selected in the group consisting of: C, N, S, O, a group -CH-, and a group -NH-, in such a combination that the resulting ring formed is an aromatic system;

R¹⁹ is selected from the group consisting of: hydrogen, -CF₃, -NR^ER^F, -(C₃-C₇cycloalkyl), -(C₃-C₇heterocycloalkyl), aryl or heteroaryl wherein any of such -(C₃-C₇cycloalkyl), -(C₃-C₇heterocycloalkyl), aryl or heteroaryl may be optionally substituted by a group C₁-C₆ alkyl, C₃-C₇ cycloalkyl, or halo; or

R¹⁹ is a group of general formula (V)



wherein R²⁰, R²¹, R^E and R^F are as above defined;

T is -N= or -CR²³=;

R²³ is H, halo, -CH₃, or -CN;


R²² is H, halo, -CH₃, or -CN;

q is 0, 1, 2 or 3;

~~with the proviso that when Y is a group O(CR³R⁴)_n, n is 1 and R¹⁰ is~~
~~-NR^AR^B, -N(R^C)C(O)-(C₄-C₆alkylene)-NR^AR^B, -N(R^C)C(O)-(C₃-C₇cycloalkylene)-~~
~~NR^AR^B, -N(R^C)C(O)N(R^AR^B), -N(R^C)C(O)N(R^C)-(C₂-C₆alkylene)-NR^AR^B, -~~
~~N(R^C)C(O)N(R^C)-(C₃-C₇cycloalkylene)-NR^AR^B, or~~


$\text{N}(\text{R}^{\text{E}})\text{C}(\text{O})\text{R}^{\text{E}}$, then X_4 is nitrogen.

2. A compound of formula (I) according to claim 1 which is a compound of formula (Ia) wherein carbon stereogenic center on the cycloalkylene portion of ring A which is linked to group W and identified with number (1) herebelow, possess the absolute configuration herebelow represented:



- 10 Or a pharmaceutically acceptable salt thereof.


3. A compound of formula (I), according to claim 1 or 2, which is a compound of formula (Ib) wherein carbon stereogenic centers on the cycloalkylene portion of ring A which are linked to group W and Y and identified, respectively, with numbers (1) and (2) herebelow, possess the absolute configuration herebelow represented:




Or a pharmaceutically acceptable salt thereof.

20

4. A compound of formula (I) according to anyone of claims 1 to 3 wherein A is group selected in the group consisting of:






Or a pharmaceutically acceptable salt thereof.

5. — A compound of formula (I) according to anyone of claims 1 to 4 wherein W is NH or O, or a pharmaceutically acceptable salt thereof.

6. — A compound of formula (I) according to anyone of claims 1 to 5 wherein Y is $S(O)_p$, a group $O(CR^3R^4)_n$, $(CR^5R^6)_n$, or a group NR^7 ; p is zero and n is 0, 1 or 2, or a pharmaceutically acceptable salt thereof.


57. A compound of formula (I) according to anyone of claims 1 to 46, wherein R^1 is a group of formula (IIc):




(IIc)

or a pharmaceutically acceptable salt thereof.

68. A compound of formula (I) according to anyone of claims 1 to 57, wherein W is NH, Y is a group $O(CR^3R^4)_n$ and n is 0, A is group:




Wherein R^1 is a group of formula (IIca) as above defined which is connected to the group Y through the carbon adjacent to X^2




- 5 And wherein X^4 is a carbon atom, X^5 is a nitrogen atom, X^3 is a nitrogen atom and X^2 is a group $-CH-$, and R^{13} is hydrogen;

Wherein R^{11} is a group:




- 10 Wherein R^{25} is optionally present and represents one, two or three substituents independently selected in the list consisting of: C_1 - C_6 alkyl, $(C_1$ - $C_3)$ haloalkyl, $(C_1$ - $C_4)$ hydroxyalkyl, C_3 - C_7 cycloalkyl, hydroxyl and halo; and wherein the asterisk represents the point of attachment for group R^{11} to the rest of the molecule via X^4 ;
Wherein R^2 is a radical of formula (IIIb):



(IIIb) ;

Wherein $z^1 = -CH-$, $z^2 = C$, z^3 and z^4 are N and R^{17} is a group of general formula (IV)




5


And Wherein R^{20} is $-CH_3$ or $-CH_2OH$, and R^{21} is $-CH_3$.

79. A compound of formula (I) according to anyone of claims 1 to 57,
wherein W is NH, Y is a group $O(CR^3R^4)_n$ and n is 0, A is group:

10



Wherein R^1 is a group of formula (IIca) as above defined which is connected to the group Y through the carbon adjacent to X^2




(IIca)

15 And wherein X^4 is a carbon atom, X^5 is a nitrogen atom, X^3 is a nitrogen atom and


X^2 is a group $-CH-$, and R^{13} is hydrogen;

Wherein R^{11} is a group:




- 5 Wherein R^{25} is optionally present and represents one, two or three substituents independently selected in the list consisting of: C_1 - C_6 alkyl, (C_1-C_3) haloalkyl, (C_1-C_4) hydroxyalkyl, C_3 - C_7 cycloalkyl, hydroxyl and halo; and wherein the asterisk represents the point of attachment for group R^{11} to the rest of the molecule via X^4 ; Wherein R^2 is a radical of formula (IIIb):

10



(IIIb) ;

Wherein $z^1 = -CH-$, $z^2 = C$, z^3 and z^4 are N and R^{17} is a group of general formula (IV)



15

And Wherein R^{20} is $-CH_3$ or $-CH_2OH$, and R^{21} is $-CH_3$.

840. A pharmaceutical composition comprising a compound as claimed in any of the preceding claims 1 to 79, together with one or more pharmaceutically

acceptable carriers.

| 911. A compound as claimed in any of claims 1 to 79 for use in the treatment of diseases or conditions which benefit from inhibition of p38 MAP kinase activity.

5

| 1012. Compounds according to anyone of claims 1 to 79 for use in the treatment of diseases or conditions which benefit from inhibition of p38 MAP kinase activity according to claim 911 wherein the diseases or conditions is chronic eosinophilic pneumonia, asthma, COPD, adult respiratory distress syndrome (ARDS),
10 exacerbation of airways hyper-reactivity consequent to other drug therapy or airways disease that is associated with pulmonary hypertension.

| 1113. The use of a compound as claimed in any of claims 1 to 79 in the manufacture of a medicament for the treatment of diseases or conditions which
15 benefit from inhibition of p38 MAP kinase activity.

| 1214. The use according to claim 1113 wherein the disease or condition is chronic eosinophilic pneumonia, asthma, COPD, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug
20 therapy or airways disease that is associated with pulmonary hypertension.